The U.S. FDA has approved TREMFYA® (guselkumab) for adults with moderate to severe ulcerative colitis, bolstering Johnson & Johnson's position in the inflammatory bowel disease market.

Beijing QL Biopharmaceutical revealed Phase 1c clinical results for its primary drug candidate ZT002 at the EASD Annual Meeting 2024.

Cytokinetics, Incorporated (Nasdaq: CYTK) disclosed that data from the Phase 1 clinical trial of CK-4021586 (CK-586) were showcased during a poster presentation at the ACCP Annual Meeting.

CytomX Therapeutics reports initial patient treatment with CX-801, a dual-masked Interferon-Alpha 2b PROBODY®, in a Phase 1 trial for solid tumor patients.

Zealand Pharma reveals encouraging top-line outcomes from a 13-week Phase 1b trial of their GLP-1/GLP-2 receptor dual agonist dapiglutide.

Moleculin Reports Initial Patients Treated in Phase 2 Trial Combining STAT3 Inhibitor with Radiation for Glioblastoma Therapy.

Boehringer's zongertinib demonstrates promising effectiveness and tolerability in patients with HER2-mutated lung cancer who have undergone prior treatment.

Phanes Therapeutics reported that the first patient has received a dose in the clinical trial of PT886 alongside chemotherapy.

Clear Scientific Reveals Positive Initial Clinical Trial Results for CS-1103, a Novel Treatment for Meth and Fentanyl Overdose.

Ractigen Shares Encouraging Clinical Results for RAG-17 in ALS-SOD1 Therapy from Independent Study.

Insulin efsitora alfa, administered weekly, achieves comparable A1C reduction to daily insulin in adults with type 1 diabetes.

Recent findings on the investigational drug BAY 2927088 for HER2-mutant non-small cell lung cancer (NSCLC) showcased at WCLC.